Compelling evidence that chronic neuroinflammation induces neurodegeneration in Parkinson's disease (PD) Hypothesized that microglial inflammasome activation propagates chronic neuroinflammation in PD IC 100, a CNS-penetrating monoclonal ASC Inhibitor, targets multiple types of inflammasomes to
ZyVersa is a clinical stage biopharmaceutical company developing first-in-class product candidates to address significant unmet medical needs of patients with renal and inflammatory diseases Lead renal product candidate, phase 2a-ready VAR 200, mediates removal of excess intracellular lipids that
Video features researchers at the University of Miami Miller School of Medicine: Dr. Alessia Fornoni, Katz Professor of Medicine, Chief, Katz Family Division of Nephrology & Hypertension & Director of Peggy & Harold Katz Drug Discovery Center Dr. Sandra Merscher, Research Associate Professor, Katz
ANNUAL INFLAMMASOME SUMMIT UNITES WORLD RENOWNED EXPERTS IN INFLAMMASOME-TARGETED DRUG DEVELOPMENT AND ACADEMIA TO SHARE INFORMATION AND ADDRESS KNOWLEDGE GAPS IN THIS RAPIDLY EVOLVING FIELD ZYVERSA IS WELL POSITIONED IN THE EMERGING INFLAMMASOME SPACE WITH A HIGHLY DIFFERENTIATED INFLAMMASOME ASC
ANNUAL INFLAMMASOME SUMMIT UNITES WORLD RENOWNED EXPERTS IN INFLAMMASOME-TARGETED DRUG DEVELOPMENT AND ACADEMIA TO SHARE INFORMATION AND ADDRESS KNOWLEDGE GAPS IN THIS RAPIDLY EVOLVING FIELD ZYVERSA IS WELL POSITIONED IN THE EMERGING INFLAMMASOME SPACE WITH A HIGHLY DIFFERENTIATED INFLAMMASOME ASC
ZYVERSA IS WELL POSITIONED IN THE RAPIDLY EMERGING INFLAMMASOME SPACE WITH A HIGHLY DIFFERENTIATED INFLAMMASOME ASC INHIBITOR, IC 100, WHICH HAS POTENTIAL TO TREAT A BROAD RANGE OF INFLAMMATORY DISEASES ZYVERSA'S PIPELINE INCLUDES VAR 200, A PHASE 2A-READY FIRST-IN-CLASS CHOLESTEROL EFFLUX MEDIATOR
